Genetics of Type 2 Diabetes in West Africans
|First Submitted Date||February 4, 2009|
|First Posted Date||February 5, 2009|
|Last Update Posted Date||October 31, 2017|
|Start Date||February 3, 2009|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures||Not Provided|
|Original Primary Outcome Measures||Not Provided|
|Change History||Complete list of historical versions of study NCT00837122 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures||Not Provided|
|Original Secondary Outcome Measures||Not Provided|
|Current Other Outcome Measures||Not Provided|
|Original Other Outcome Measures||Not Provided|
|Brief Title||Genetics of Type 2 Diabetes in West Africans|
|Official Title||Genetics of Tye 2 Diabetes in Diverse Populations|
|Detailed Description||This research protocol is designed to study the genetic basis of Type 2 Diabetes (T2D) in a broad range of populations in the United States and abroad. This project takes advantage of the well established infrastructure and success of Dr. Rotimi s international genetic epidemiology study of T2D funded as an R01 grant by NIDDK while he was at Howard University. This parent project is ongoing in four major ethnic groups in Nigeria (Yoruba and Ibo) and Ghana (Akan and Gaa). At completion in 2013 and given current projections, we anticipate enrolling about 2,000 cases and 2000 controls from the five centers in West Africa (Enugu, Ibadan and Lagos in Nigeria; Accra and Kumasi in Ghana). However, current projection indicates that the enrollment of Yoruba cases and controls will be short by about 300 cases and 300 controls. It is critically important to supplement the enrollment of Yoruba participants from another community in the Ibadan metropolitan area in Nigeria. Therefore, the original goal of the current project is to enroll additional 300 cases of T2D and 300 ethnically matched Yoruba controls to facilitate the conduct of genome-wide association study (GWAS) and candidate gene/loci studies in West Africans. Other current and future projects will increase the number of subjects for future genome-wide association studies (GWAS), linkage disequilibrium (LD) mapping, and functional studies in different ethnically-defined populations. Each project will aim to enroll ethnically balanced cases and controls with the goal of facilitating the conduct of GWAS and candidate gene/loci studies in a broad range of populations. Overall, these studies aim to further (or in some cases be the first) such large-scale efforts to understand the genetic basis of T2D in individuals of varying backgrounds including African and Mexican ancestries. Identified candidate genes/loci will be investigated by re-sequencing and functional studies will be conducted to identify susceptibility variants for diabetes and associated complications including obesity, hypertension, nephropathy, neuropathy and retinopathy. Additionally, these samples will be used to study genetic variation in the context of how participants of different ancestry respond to drugs and other environmental factors and how this variation may have shaped population history. Given past activities, it is also anticipated that this resource will form the basis of multiple collaborations between Dr. Rotimi s lab, several NIH intramural researchers and non-NIH scientists. Each subsequent population that is added to this study over time will use the same procedures that were originally approved for ongoing work among West Africans.|
|Study Design||Time Perspective: Prospective|
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
|Study Groups/Cohorts||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Completion Date||Not Provided|
|Primary Completion Date||Not Provided|
Cases Men and women with confirmed type 2 diabetes mellitus that are either on treatment for diabetes or newly diagnosed with blood sugar reading on more than one occasion exceeding or equal to 126 mg/dl. These persons must be above the age of 25 years. In this regard, all newly diagnosed participants will be required to visit the clinic on the following day to perform a fasting blood glucose test to confirm previous results.
Controls Men and women with fasting plasma glucose (FPG) less than 100 mg/dl (5.6 mmol/l). Controls must be above age 25 years and should be ethnically matched to the cases. Enrolled cases and controls have to be unrelated. Therefore, only one person may be enrolled from each family unless they are husband and wife.
Attempts will be made to enroll an equal number of men and women. To ensure that ethnic distribution is maintained in each study, we are proposing to enroll ethnically-matched participants relevant to each study.
People who do not meet the above criteria (e.g., younger than 24, without the blood sugar requirements, etc). No more than one non-spouse member of each family. No prisoners, pregnant women or fetuses will be included in this study.
|Ages||26 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||Yes|
|Listed Location Countries||Kenya, Nigeria|
|Removed Location Countries|
|Other Study ID Numbers||999909070
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )|
|Study Sponsor||National Human Genome Research Institute (NHGRI)|
|PRS Account||National Institutes of Health Clinical Center (CC)|
|Verification Date||October 26, 2017|